ERBB2 and breast carcinoma: Patients with HER2+ breast cancer are usually treated with a combination of trastuzumab and taxanes with or without other chemotherapeutic agents [1-3], but predictors that indicate the response to the chemotherapy and outcome are not fully investigated.